Three words do a lot of quiet work in depression treatment: approved, cleared, and off-label. They show up on clinic websites, in insurance letters, and in news stories, usually without explanation. If you are weighing a treatment and FDA status matters to you, knowing what each word means will help you ask better questions.

And FDA status does matter to most people. This summer we commissioned a poll of 443 Midwest adults across ten states, and 59 percent of them gave FDA approval big or deciding weight in judging an unfamiliar depression treatment; 19 percent said it alone would settle the matter. Those are final numbers, checked in Pollfish's validation.

"FDA-approved": the drug standard

When a drug is FDA-approved, the manufacturer has submitted evidence, usually from clinical trials, showing the drug is safe and effective for one defined use in one defined group of patients. The FDA reviews that evidence and approves the drug for that use. The approved use goes on the official label.

Two points are easy to miss. First, approval is tied to a specific condition and does not carry over to another. Second, approval is not a promise that the drug will work for you. It means the evidence showed benefit outweighing risk across the studied population.

In depression care: Standard antidepressants are FDA-approved for depression. Spravato, the brand name for esketamine, holds FDA approval specifically for depression that has not yielded to other treatment. The nasal spray may only be used under staff supervision in a certified clinic.

"FDA-cleared": the device pathway

Medical devices usually go through a different process. Many are "cleared" through a pathway in which a maker demonstrates its device is substantially equivalent to something already sold, or through other routes reserved for devices. Clearance still involves FDA review, but it is a different kind of review than drug approval, and the word is chosen deliberately.

In depression care: TMS, short for transcranial magnetic stimulation, places a magnetic coil on the scalp to stimulate brain tissue involved in mood. For adults whose major depression has not responded to antidepressants, TMS devices have FDA clearance. When a TMS clinic says "FDA-cleared," that is the accurate term, and it is a legitimate one.

"Off-label": legal, common, and worth asking about

Once a drug is approved for anything, a licensed prescriber may legally use it for a different condition, dose, or population. That is called off-label use. It is common across medicine, and it is not inherently wrong. Sometimes the evidence for an off-label use is strong. Sometimes it is thin.

What off-label means for you is that the specific use has not gone through FDA review. The evidence behind it may come from smaller studies, clinical experience, or professional guidelines rather than the formal approval process.

In depression care: Ketamine in its generic form carries approval as an anesthetic. A clinic that infuses it to treat depression is using it off-label. Lozenges or tablets mailed out after a telehealth visit are off-label as well, and may be compounded.

"Compounded": made to order, not FDA-approved

A compounded medication is prepared by a pharmacy for an individual patient, often in a form or dose not commercially available. No compounded drug holds FDA approval, and none gets FDA review for safety, effectiveness, or quality before a patient receives it, though pharmacies are regulated in other ways.

REMS: approval with conditions

Some approved drugs come with a REMS, which stands for Risk Evaluation and Mitigation Strategy: a set of safety requirements the FDA attaches to an approval when a drug has serious risks.

In depression care: Spravato has a REMS. Only certified sites may give it, each dose is followed by two or more hours of observation, and driving is off the table until the following day. So there is no picking it up from a pharmacy counter for use in your kitchen. Brain Recovery Centers describes what a supervised Spravato session looks like under these rules. The restrictions are part of the approval, not a sign that something is wrong with it.

Putting the labels side by side

Why most people cannot tell these apart

Awareness is low. Spravato was a new word to 73 percent of the people we polled, close to three in four, and a mere 6 percent could explain it. Nor do people search by treatment name: the 319 who told us what they would type into Google offered phrases like "ptsd treatments" and "depression medicine alternatives."

Where FDA status ranks against other concerns

FDA approval matters, but it is not the only thing. Given two picks for what matters in a provider, respondents put insurance coverage far in front at 85 percent, with nearness to home second at 43 percent. Approval by the FDA landed at 27 percent, a nose ahead of fast results at 24 percent. Most people appear to treat approval as a baseline and then compare on cost and convenience.

Questions to ask about any depression treatment

Most people in our survey would ask their doctor, and 74 percent said that doctor's say-so would tip them toward trying a treatment. Which label, if any, belongs in your care is for a clinician familiar with you to sort out.

Labels can wait; your safety cannot. With thoughts of suicide, text or ring 988 and a Suicide and Crisis Lifeline counselor will respond, day or night.

Methodology

Data come from Pollfish survey 395586438, run on the company's panel of consumers; it closed June 23, 2026, and its 443 completes are adults 18 to 64 in Nebraska, Ohio, Iowa, Indiana, Missouri, Wisconsin, Oklahoma, Illinois, Minnesota and Kansas, each of whom passed a consent question. A multi-select figure is the percentage of the full sample choosing that option. Its validated results are final. The publisher paid for and commissioned the work.